Galux

Galux was established in 2020 with the incorporation of molecular design technology that has been honed over a period of 15 years at Seoul National University. This technology leverages the integration of AI, physics, and chemistry to produce exceptional results, as evidenced by its performance in the CASP and CAPRI competitions. Built on a foundation of advanced research and development capabilities, Galux is currently developing a drug design platform that incorporates protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction technologies. The company is also focused on identifying and developing novel therapeutics for incurable and rare diseases through its...

Artificial intelligence,neural network,machine learning,drug discovery,drug design,drug development,biological drug,protein drug,antibody drug,enzyme drug,chemical drug,small molecule drug,and large molecule drug

Galux operates in the Biotechnology research industry.

Galux's revenue is 11m - 100m

Galux has 11 - 50 employees.